Research Report for Verisk Analytics, Inc.(NASDAQ:VRSK): Teva Pharmaceutical Industries Limited(NYSE:TEVA)

0
2

Verisk Analytics, Inc. (VRSK) will report its next earnings on Feb 18 AMC. The company reported the earnings of $1.13/Share in the last quarter where the estimated EPS by analysts was $1.12/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 0.9%.

Many analysts are providing their Estimated Earnings analysis for Verisk Analytics, Inc. and for the current quarter 14 analysts have projected that the stock could give an Average Earnings estimate of $1.13/share. These analysts have also projected a Low Estimate of $1.06/share and a High Estimate of $1.18/share.

In case of Revenue Estimates, 10 analysts have provided their consensus Average Revenue Estimates for Verisk Analytics, Inc. as 685.14 Million. According to these analysts, the Low Revenue Estimate for Verisk Analytics, Inc. is 654.55 Million and the High Revenue Estimate is 708.47 Million. The company had Year Ago Sales of 618.38 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for VRSK to be 10.7%. They are projecting Next Quarter growth of 12.73%. For the next 5 years, Verisk Analytics, Inc. is expecting Growth of 11.53% per annum, whereas in the past 5 years the growth was 12.33% per annum.

Some buy side analysts are also providing their Analysis on Verisk Analytics, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

The Relative Volume of the company is 1.47 and Average Volume (3 months) is 744.97 million. The company’s P/E (price to earnings) ratio is 62.02 and Forward P/E ratio of 30.74.

The company shows its Return on Assets (ROA) value of 6.9%. The Return on Equity (ROE) value stands at 20.7%. While it’s Return on Investment (ROI) value is 10.7%.

While looking at the Stock’s Performance, Verisk Analytics, Inc. currently shows a Weekly Performance of -2.22%, where Monthly Performance is 1.5%, Quarterly performance is 16.1%, 6 Months performance is 6.03% and yearly performance percentage is 34.03%. Year to Date performance value (YTD perf) value is 12.21%. The Stock currently has a Weekly Volatility of 2.29% and Monthly Volatility of 1.53%.

Teva Pharmaceutical Industries Limited (TEVA) will report its next earnings on Feb 12 BMO. The company reported the earnings of $0.62/Share in the last quarter where the estimated EPS by analysts was $0.61/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 1.6%.

Many analysts are providing their Estimated Earnings analysis for Teva Pharmaceutical Industries Limited and for the current quarter 15 analysts have projected that the stock could give an Average Earnings estimate of $0.58/share. These analysts have also projected a Low Estimate of $0.51/share and a High Estimate of $0.64/share.

In case of Revenue Estimates, 14 analysts have provided their consensus Average Revenue Estimates for Teva Pharmaceutical Industries Limited as 4.14 Billion. According to these analysts, the Low Revenue Estimate for Teva Pharmaceutical Industries Limited is 3.88 Billion and the High Revenue Estimate is 4.25 Billion. The company had Year Ago Sales of 4.33 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for TEVA to be -3.3%. They are projecting Next Quarter growth of 0%. For the next 5 years, Teva Pharmaceutical Industries Limited is expecting Growth of 7.42% per annum, whereas in the past 5 years the growth was 2.08% per annum.

Some buy side analysts are also providing their Analysis on Teva Pharmaceutical Industries Limited, where 3 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 3 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

The Relative Volume of the company is 1.45 and Average Volume (3 months) is 17.97 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 4.86.

The company shows its Return on Assets (ROA) value of -6.8%. The Return on Equity (ROE) value stands at -28%. While it’s Return on Investment (ROI) value is -3.2%.

While looking at the Stock’s Performance, Teva Pharmaceutical Industries Limited currently shows a Weekly Performance of 3.93%, where Monthly Performance is 22.23%, Quarterly performance is 21.88%, 6 Months performance is 74.93% and yearly performance percentage is -26.38%. Year to Date performance value (YTD perf) value is 29.59%. The Stock currently has a Weekly Volatility of 4.85% and Monthly Volatility of 5.02%.

SHARE